Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Closer Look: Is Double-Digit Growth Sustainable In Emerging Markets? (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

A new debate among investors concerns whether double-digit growth is possible across emerging markets or only in China. PharmAsia News takes a closer look.

You may also be interested in...



Sanofi GMP Problems Require Top-level Sit-down With FDA, But Product Impact Limited So Far

Agency’s warning letter also includes an uncommon request for a “global assessment” of operations. FDA says sterility of TheraCys lots manufactured since 2000 cannot be assured; company has halted manufacture of the bladder cancer drug and set limits on orders of its Pentacel vaccine.

Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market

Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.

China Eclipses Japan To Become Second Largest Pharma Market

Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.

Topics

Related Companies

UsernamePublicRestriction

Register

SC082094

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel